Chana R.

• Led strategic initiatives for $125M United States Agency for International Development (USAID) viral zoonoses project, enhancing pathogen detection and response capabilities in Southeast Asia, Africa, and Latin America.

• Oversaw a team of 14 staff (direct and indirect) and managed all program components including strategic planning and program design, budget, client relationship, and compliance with USG rules and regulations and the global health security standards.

• Led strategic engagement with U.S. government, host country counterparts, global health agencies (WHO, Food and Agriculture Organization, World Bank, and Asian Development Bank), and private sector (Illumina) to align priorities and resolve policy challenges.

• Created novel approach to pathogen hotspot mapping that improves validity by combining model-based insights with expert knowledge, allowing countries to better predict where an outbreak may occur and choose effective surveillance sites, leading to reduced costs for additional sites and increased accuracy of outbreak detection. Paper published in

• Oversaw the development of the first-of-its-kind biosecurity framework, coordinating with USG agencies, host governments, and global stakeholders to strengthen health systems and enhance pathogen surveillance and response capacity for emerging health threats in high-risk regions.

• Oversaw a team of 3 and provided technical leadership and diagnostic expertise to a portfolio of infectious disease detection and surveillance projects totaling ~$50M funded by WHO, World Bank, Global Fund, CDC, USAID/State Department, GAVI, and Gates Foundation.

• Portfolio responsibility rapidly increased by 65% (from $30M to $50M) in 2020 due to COVID-19 programs and contributed to $10M+ in revenue from 2018 to 2021.

• Directed USAID-funded COVID-19 and Ebola Virus Disease response efforts across 20 countries in Africa, Asia, and Latin America, working with manufacturers (Cepheid, Molbio, Roche, Abbott) and regulatory authorities to introduce new technologies, increasing diagnostic capacities and strengthening surveillance. ○ Introduced manual antigen Rapid Diagnostics Tests and validated a COVID-19 cartridge from Cepheid for its automated platform. ○ In select countries, increased testing capacity between 20 and 70% resulting in thousands of people being tested, diagnosed, and treated.

• Managed a technical team of 6 (direct and indirect) to advance operational research for the International Development Group's $100M portfolio. Direct management of ~$10M worth of family planning (FP) and maternal, newborn, and child health (MNCH), supply chain, human resources for health, HIV/AIDS, malaria, and tuberculosis (TB) activities.

• Led pharmaceutical and diagnostic supply chain and health impact evaluations in Ghana, Malawi, and Guatemala generating evidence-based policy decisions to increase market and patient access for family planning and reproductive healthcare. Most notably, evaluations revealed the following: ○ In Ghana, last mile health commodity distribution through 3rd party logistic providers increased product availability due to reduction in lead-time variability. In Guatemala, participatory monitoring mechanisms such as suggestion boxes at clinic sites, hotlines, and mobile technology increased community utilization of public health services. Developed supply chain KPIs based on client impact to evaluate supply chain performance.

• Designed and led human-centered design proposals to improve healthcare service delivery in Nigeria; identified system gaps and locally driven, scalable solutions aligned with client and government priorities.